Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen 1Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen 1Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen

1Q Revenues: $3.6 billion (-2%)

1Q Earnings: $1.1 billion (+2%)

Comments: Worldwide sales of Aranesp decreased 25% to $761 million, with U.S. sales down 38% to $405 million due to prescribing restrictions as a result of adverse cardiovascular events. Epogen sales were $554 million (-11%) due to a reduction in dose/utilization due to ESA label changes and implementation of the Erythropoietin Monitoring Policy (EMP). Combined sales of Neulasta and Neupogen were $1.1 billion (+7%). Sales of Enbrel were $951 million (+30%). Sensipar sales were $133 million (+27%). R&D expenses were $661 million (-18%), reflecting cost recoveries derived from licensing transactions with Daiichi Sankyo and Takeda in Japan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters